Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Eagle Pharma To Discuss First Quarter 2017 Financial Results On May 8, 2017 April 24, 2017 Why Gilead Could Take Out Juno But Face Major Competition From This Biotech Giant August 29, 2017 The Search is Over: Struggling Teva Finally Gets a New CEO September 10, 2017
